---
search:
  boost: 2 
---

# Irritable Bowel Syndrome (IBS) with Diarrhea

This is a subcategory of Gastrointestinal Agents.

## Decision Tree

- [IBS with Diarrhea- Non-Preferred - Alosetron, Viberzi](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUOUlHRjU4TEFRNUpEQlJCU0hPSjdEUEs5ViQlQCN0PWcu&topview=Preview){ :target="_blank" rel="noopener"}
- [IBS with Diarrhea- Step Therapy - Xifaxan](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURFE5MlhHV01LSDJKUFpKMVAzMjA2UDRVMiQlQCN0PWcu&topview=Preview){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                | Generic Name                  | Quantity | Time (Days) |
| :----------------------- | :---------------------------- | :------: | :---------: |
| Diphenoxylate / Atropine   |                               |          |             |
| Loperamide <sup>QL</sup> | Loperamide HCI Cap & Tab 2 MG |    80    |     34      |
| Xifaxan <sup>ST</sup>    |                               |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Alosetron     |              |          |             |
| Viberzi       |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria 

### Step Therapy

Step Therapy Approval Criteria

- Must have had an inadequate clinical response of at least **30 days** with at least **one
preferred** drug

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** with at least **two preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=66){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=23){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
